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Introduction
There has been an increase in treating pregnant women with 
cancer and scientists suggest that the change in trend is due to 
older women conceiving. Reports indicate that cancer is diag-
nosed in approximately 1 in 1000-1500 pregnancies (Voulgaris, 
et al., 2011). If cancer treatment cannot be postponed until after 
birth, ethical concerns arise with regard to the health of the 
mother and fetus, and so the benefits and side-effects need to be 
discussed by patient, oncologist, and obstetrician. Factors that im-
pact treatment include cancer type and stage, gestational age and 
consequences of treatment on the mother and fetus. In addition, 
risks, treatments and, if necessary, the option of abortion must be 
determined. The goal is to determine if and at what gestational 
age treatment should be given, whether cytotoxic drugs admin-
istered to the mother impacts the development of the fetus and 
results in long-term risks for the child. 
Methods
Information and research was obtained through Ebsco, Proquest 
and Pubmed. Access was provided by Touro College library. Main 
key words included pregnancy, short-term, long-term, transpla-
cental, in utero, fetus, and chemotherapy.
Discussion
Transplacental Transfer
To first address the impact of transplacental transfer, it is essen-
tial to determine if there is drug transfer between the mother 
and the fetus, and if so, to what extent. A mouse model using 40 
pregnant mice was studied to determine the amount of trans-
placental transfer of chemotherapeutic agents, doxorubicin, epi-
rubicin, cytarabine, paclitaxel, carboplatin and vinblastine. Due to 
the difference of drug metabolism in mice, the drugs were given 
at proportionately higher dosages than when given to humans. 
Fetal and maternal blood was collected on day eighteen and a 
half, during the phase of fetal development. The mice were deliv-
ered by caesarean section ninety minutes (an arbitrary amount 
of time) after chemotherapeutic drugs were intravenously given 
to the mother. At this point in time, an increase in plasma levels 
ensured drug detection and was the first phase of distribution 
after the drugs were intravenously administered.  The drug lev-
els in the maternal and fetal plasma were detected using two 
methods. High performance liquid chromatography determined 
the amount of the five chemotherapy drugs and Atomic absorp-
tion spectrometry determined carboplatin levels, based on the 
amount of platinum in the blood.  
Plasma Drug Analysis 
Paclitaxel was found in maternal plasma, but was not detected 
in fetal plasma. It has a high molecular weight, is highly protein 
bound and is a substrate of P—glycoprotein (ATP-binding cas-
sette transporters) and multidrug resistance protein. P—glyco-
protein is found in fetal-derived epithelial cells which forms the 
maternal-fetal blood exchange border and protects the fetus. 
Vinblastine and anthracyclines, which includes epirubicin, a 
4′-epimer of doxorubicin, and doxorubicin, only presents as a 
small transfer ratio due to being P-glycoprotein substrate, which 
protects the fetus against xenobiotics’ harmful effects. Another 
factor is that it possesses pharmokinetic properties that contrast 
to the substances that cross the placenta. Thus, one can imply 
that vinblastine, anthacyclines and paclitaxel present a safe option 
for treatment when given in small dosages during the last two 
trimesters. 
However, both carboplatin and cytarabine have high transfer rates 
and can penetrate the membranes barriers since they are slightly 
bound and have a low molecular weight. Therefore, researchers 
recommended, if possible, avoiding these drugs (Calsteren, et al., 
2010; Van Calsteren et al., 2010)
The transplacental transfer is generally through passive diffusion 
and is typically penetrable. However, there are three factors that 
influence the maternal-fetal transfer.  They are: (1) maternal and 
fetal circulation concentration gradient, (2) the placental blood 
flow, and (3) chemotherapy’s drug properties.  The pharmok-
inetics of chemotherapy that favor transplacental transfer are 
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uncharged, low molecular weight, lipid soluble, and unbound or 
low protein bound compounds (Calsteren, et al., 2011).
Maternal- Fetal Transfer in a Baboon Model
The data obtained from the previous experiment, however, is 
limited in its clinical application due to the differences of human 
and mouse metabolism and permeability and formation of the 
placenta (Van Calsteren, et al., 2011). This elicited further inves-
tigation of the effects of maternal-fetal transfer of chemothera-
peutic agents given in second and third trimesters. Two studies, 
using the same subjects, examined the results of different che-
motherapeutic drugs on a group of nine pregnant baboons. Data 
more relevant to humans can be obtained from baboon models 
as compared to mice models due to the greater similarity of 
human and baboon embryological development, placental struc-
ture and function, reproductive physiology and endocrinology of 
pregnancy and drug metabolism. Based on the outcome, since 
only low levels were detected, the authors were reassured that 
the use of doxorubicin, epirubicin, vinblastine, taxanes (docetaxel 
and paclitaxel) and active metabolite of cyclophosphamide (4-
OHPC) were not damaging to the fetus. However, they were 
concerned with the results of trastuzumab and carboplatin since 
they were transferred in large or complete amounts. The study 
was limited since there was no record of long term results, and 
it was suggested that further research needed to be performed 
(Calsteren, et al., 2010).  Furthermore, other medical profession-
als contraindicate trastuzumab since it has been correlated with 
oligohydramnios, reduced production of amniotic fluid resulting 
from the drug binding to fetal renal receptors (Gziri, et al., 2012). 
Placental Perfusion Model
As it would be unethical to perform human testing on pregnant 
women to determine whether there is maternal-fetal transfer 
due to fetal risk of fetal blood sampling from the umbilical cord 
known as cordocentesis, Van Calsteren et al. (2011) suggested 
that they can be applied to a single cotyledon models that have 
separate fetal and maternal circulations. Unfortunately, some 
complications with this proposal included difficulties obtaining 
absolute physiological conditions in a perfusion system, tempo-
rary status of tissue viability, and the differences in data between 
in vivo and placenta perfusion model with some drugs (Myllynen, 
Vhakangas, 2002; Van Calsteren, et al., 2011).
An attempt was made, however, to examine the effects of ma-
ternal-fetal transfer of taxanes (paclitaxel and docetaxel) to de-
termine whether it can be a viable treatment option. The single 
cotyledons were taken from twelve placentas from uneventful 
pregnancies with each test group containing six models. The test 
groups were further divided into two groups of three, with one 
group containing high concentration of albumin (30 g/L) and the 
other group with low concentration of albumin (2 g/L). In the 
intervillous space two catheters were inserted to begin the per-
fusion and the twelve placentas were perfused for ninety min-
utes.  The results indicated that taxanes have a low transplacental 
transfer due to their chemical properties and added that there 
was no difference in amount of drug transfer between paclitaxel 
and docetaxel. Furthermore, the outcome between the groups of 
high and low levels of albumin reinforced the theory that protein 
levels affect the maternal-fetal transfer. This was supported with 
the observation of less transfer of both docetaxel and paclitaxel 
with high levels of albumin. Although this reinforced previous 
studies of placental transfer, sample size was too small and fur-
ther investigation should be performed (Berveiller, et al., 2012). 
Factors and Effects of Chemotherapeutic Drugs
Based on research that positively indicated transplacental trans-
fers of chemotherapeutic drugs, studies were initiated to deter-
mine the drug effect on the developing fetus. There are four main 
drugs that are typically administered to pregnant cancer patients. 
They are:  anthracyclines (e.g., doxorubicin, epirubicin), plati-
num-based antineoplastics (e.g., cisplatin, carboplatin), cyclophos-
phamide and taxanes (e.g., paclitaxel, docetaxel). Anthracyclines 
result in cardiotoxicity and inhibit topoisomerase, interfering 
with DNA replication. Platinum based antineoplastics result in 
neurotoxicity and ototoxicity if given at high doses. It also allows 
for apoptosis to occur since it binds to and causes crosslinking of 
DNA. The effect of cyclophosphamide is permanent infertility if 
given at high dosage. Lastly, taxanes disrupt the microtubule func-
tion in cell division thereby inhibiting mitosis (Vandenbroucke, et 
al., 2014). The overall similarity between them is that they halt 
normal cell proliferation cycles which results in interrupting cru-
cial cell processes. Studies on somatic cell mutations report that 
some adverse effects of chemotherapy are gene mutations, chro-
mosomal breaks and rearrangements, and aneuploidy (Arnon, et 
al., 2001).
The impact of chemotherapy on the fetus can vary due to phys-
iologic changes in the pregnant patient. Some examples that may 
occur include an increase in glomerular filtration, which increases 
the amount of elimination or drug excreted by the kidney, and an 
increase of drug metabolization in the liver, which might impact 
the presence of active drugs. Additionally, there is an increase in 
entero-hepatic circulation in pregnant women. This causes active 
metabolites to return to the liver and then colon after being 
secreted from bile into the colon and reabsorbed by enterocytes. 
The circulation prolongs the drug exposure since it lengthens 
the time needed to eliminate the drug from the body because it 
returns to the blood stream. The amount of active drugs available 
can decrease due to an increase in protein binding which results 
in a greater impact of cytotoxic drugs. However, plasma levels 
of cytotoxic drugs may be reduced as a result of an increase in 
plasma concentration (Amant, et al., 2008). The third space that 
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develops in pregnant women resulting from an increase of amni-
otic fluid can also impact the distribution volume of chemother-
apy, causing a slow release of drug which results in an increase 
of fetal chemotherapy exposure (Williams, Schilsky, 2000). Other 
factors that impact the maternal chemotherapy on the fetus are 
metabolic activity and excretion of the placenta, increase of body 
fat of the pregnant patient and pH difference between maternal 
and fetal fluids (Gedeon, Koren, 2006). When creating a treat-
ment plan, these physiologic changes must be considered.
Various other factors can also result in teratogenic risks to the 
fetus. Although the placenta can excrete fetal waste products and 
assist in fetal drug elimination, some antineoplastic agents may 
not be eliminated from the fetus if drugs are administered close 
to delivery time. Additionally, due to the fetus’s immature liver 
and kidney, the fetal metabolism and excretion of the chemo-
therapeutic drugs may be abnormal. This can result in an increase 
of chemotherapy exposure and acute toxicity (Williams, Schilsky, 
2000).
Administration Variables
The effect on the fetus is not only dependent on drug type and 
performance, but is also based on dose, route and gestational 
age. Studies have proven higher toxicity can develop from short 
infusions, topically applied cytotoxic agents and intraperitoneal 
administration.¬ Drugs given orally may be absorbed less due 
to a decrease of elimination from the stomach and intravenous 
administration can result in fetal risks. As mentioned previously, 
prolonged drug elimination from the mother also impacts the 
toxicity on the fetus (Wiebe, et al., 1994).
Chemotherapy Exposure- Fertilization/
Implantation
To determine the effect of chemotherapy on the developing 
embryo and fetus, observations were performed during the 
three stages of pregnancy. The three phases of fetal develop-
ment are fertilization/implantation, organogenesis, and the fetal 
phase. Chemotherapy is cytotoxic, thereby inhibiting cell growth. 
Therefore, exposure during the first ten days of pregnancy, the 
stage of fertilization/implantation, results in an all-or-nothing phe-
nomenon. Cells are omnipotent and may develop into the three 
different embryological layers, ectoderm, mesoderm and endo-
derm. However, their ability to develop normally is dependent 
on the impact of maternal chemotherapy. If there is a sufficient 
amount of cells, the embryo will develop normally, but a miscar-
riage can occur if too many cells are destroyed by the chemo-
therapeutic drug (Reed, et al., 2010). 
Chemotherapy Exposure- Organogenesis
During the first trimester, it is highly inadvisable to treat the 
mother with cytotoxic drugs.  Voulgaris et al. reports (2011) that 
there is a 10-20% chance of teratogenicity, fetal malformation, 
occurring if agents are administered in the first trimester. An in-
crease of embryonic death can occur if there is damage to the 
embryo in the first month of gestation resulting from chemother-
apy exposure (Voulgaris, et al., 2011).  Spontaneous abortion and 
major malformations are also possible risks that can occur.  The 
fetus is more susceptible to malformations two to eight weeks 
after conception, the period of organogenesis. Specifically, the 
heart, neural tube, and limbs are more vulnerable, preceding the 
palate and ears of the fetus. If chemotherapy exposure continues 
after eight weeks, the eyes, genitalia, hematopoietic and central 
nervous system still remain at risk (Cardonick, Iacobucci, 2004). 
This strongly reinforces that maternal chemotherapy should be 
avoided in the first trimester.
Chemotherapy Exposure- Fetal Phase of 
Development
Based on observations of the fetus exposed to maternal che-
motherapy during the final two trimesters, researchers have 
suggested that these exposed fetuses did not exhibit more 
congenital malformations than fetuses from untreated mothers. 
Nevertheless, intrauterine growth restriction, low birth weight 
and neonatal myelosuppression have been detected in neonates 
exposed to chemotherapy in the second and third trimester 
(Cardonick, Iacobucci, 2004; Van Calsteren, et al., 2011). From 
week eleven until delivery, functional damage will frequently 
occur as a result of cell death.  In addition, some organs may later 
develop structural anomalies. For instance, the fetus can develop 
neuropsychological impairment since the central nervous system 
is progressing throughout gestation (Vandenbroucke, et al., 2014). 
Short-term Effects -Obstetric and Neonatal 
Outcomes
One study reported on 62 patients who were treated predom-
inantly in the last two trimesters with chemotherapy alone or 
combined with other treatments, such as radiotherapy. These 
patients were part of a sample of 180 pregnant women who re-
ceived various treatments for cancer.  The results were analyzed 
to determine the fetal risks of treated and untreated mothers 
diagnosed with cancer.
Regarding patients treated with chemotherapy, there was a sig-
nificant increase in preterm labor, but not in the rate of preterm 
premature rupture of membranes (PPROM) when compared to 
neonates not exposed to maternal chemotherapy.  However, the 
only incidents of preterm labor and PPROM that occurred in the 
180 cases analyzed involved patients treated with chemotherapy. 
Preterm labor can occur from the activation of hypothalamic-pi-
tuitary-adrenal axis of either the mother or fetus resulting from 
physical or psychological stress. Scientists propose that PPROM 
can result from apoptosis in amnion epithelial and chorion 
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trophoblast layers of the membranes after maternal chemother-
apy exposure (Van Calsteren, et al., 2010).
The risks of preterm labor include intraventricular hemorrhage, 
bradycardia, apnea, respiratory insufficiency, necrotizing entero-
colitis, sepsis, seizures, hypoglycemia, and feeding problems (Van 
Calsteren, et al., 2010).  Additionally, Johnson (2007) reported 
that preterm births are associated with a decrease in IQ scores, 
cognitive delay, behavioral problems and higher risk for psychiat-
ric disorders, primarily ADHD. Preterm labor in this research was 
preventable since several of the neonatal issues were iatrogenic. 
Therefore, researchers suggested that patients that can delay 
treatment until after delivery should do so to avoid prematurity 
(Van Calsteren, et al., 2010).  
Data of small-for-gestational-age children was available for only 
175 neonates. Regarding those treated with cytotoxic treatments 
(chemotherapy and/or radiotherapy), 16 of 66 children were 
small- for- gestational age as opposed to 10 of 109 children who 
were not exposed to maternal chemotherapy/radiotherapy. 
The malformation outcome in comparison to normal pregnan-
cies reveals that there was no significant increase in rate. The 
range of physical abnormalities of neonates exposed to maternal 
chemotherapy was still within normal range, with 2 of 66 (3.0%) 
inflicted with major malformations and 5 of 66 (7.5%) affected 
with minor malformations. The average rate of major and minor 
malformations was 4.1% to 6.9% and 6.5% to 35.8%, respectively. 
This suggests that the concern of malformation defects due to 
chemotherapy is not applicable and should not deter patients 
from avoiding treatment (Van Calsteren, et al., 2010).   
Another fetal risk that may occur is transient neonatal myelosu-
pression (TNM).  Elburg et al. (2008) defined TNM as “leukopenia 
and/or neutropenia combined with anemia and/or thrombocy-
topenia, during the first weeks of life in newborns exposed to 
maternal chemotherapy during pregnancy.” The disease is rare, 
potentially life-threatening and may not necessarily develop 
right after birth. Additionally, it may pose a risk for developing 
infections. The development of TNM may result from a short gap 
between chemotherapy administration and birth, maternal neu-
tropenia at delivery, type of chemotherapy and maternal disease 
and dosage given. Treatments for TNM include thrombocyte and/
or erythrocyte transfusions, bedside isolation, erythropoietin, 
and recombinant human granulocyte colony stimulating factors 
(G-CSF).   In a study of fifteen neonates diagnosed with TNM, 
only one died due to infection resulting from TNM. However, 
the other fourteen neonates’ physical and neurological devel-
opments were normal by the age of one and their TNM was 
resolved between two to ten weeks after birth.  Generally, there 
is no difference detected in short term outcomes and survival 
rates between neonates exposed to chemotherapy that develop 
TNM and those not diagnosed with TNM. Researchers stated 
that this is true as long as the disease is recognized and aggressive 
treatment is given. However, the long-term consequences are still 
unknown (Udink ten Cate, et al., 2009).  
 Another study performed by Aviles et al. (1991) consisted of 
43 infants exposed to maternal chemotherapy. The infants were 
examined from age three through nineteen years old and it was 
observed that only eight were pancytopenic at birth, which char-
acterizes them as being deficient in red and white blood cells 
and platelets. However, the mothers of these neonates were 
treated with chemotherapy in the last three weeks prior to de-
livery which disputes the suggestion that a short gap between 
chemotherapy administration and delivery results in TNM.  There 
were no congenital anomalies and neurological abnormalities re-
ported and like the findings of the Udink ten Cate et al. (2009) 
study, the TNM resolved 2-10 weeks after birth. In addition, in a 
study of 62 patients, two children suffered postnatal hematolog-
ic toxicity (leukopenia and pancytopenia) when born ten days 
after maternal chemotherapy administration for acute lymphatic 
leukemia and required hematologic growth factors as treatment 
(Calsteren, et al., 2010). This study supports the theory, unlike 
Aviles et al. (1991) that a short interval between the chemother-
apy administration and delivery can result in hematologic toxicity. 
As seen with these results, hematologic toxicity can present a 
slight concern for pregnant women with cancer, yet the risks are 
minimal if proper treatment is given.
Cardonick and Iacobucci (2004) have studied the impact of che-
motherapy given after the first trimester on 376 fetuses. Of the 
376, nineteen of the fetuses and four of the neonates died, 28 
neonates were born with intrauterine growth restriction and 18 
were born prematurely (iatrogenic cases excluded). Additionally, 
two were diagnosed with transient neonatal cardiomyopathy due 
to maternal idarubicin treatment, fifteen neonates developed 
transient neonatal myelosuppression. Eleven malformations were 
also reported with the majority resulting from chemotherapy 
exposure in the first trimester.
Another study was performed which was composed of 61 pa-
tients receiving chemotherapy during the second and third tri-
mesters. Of the 61 patients, 32 were treated with neoadjuvant 
chemotherapy and 2 received adjuvant chemotherapy. The 61 
neonates that were exposed to maternal chemotherapy were 
examined and compared to 60 neonates who were born prema-
turely and were not exposed to maternal chemotherapy. Results 
suggested that there were no differences in birth weight, admis-
sions to the NICU, and neonatal survival. No malformations were 
reported in either group. Nonetheless, one contrast between the 
groups was the considerable difference in Apgar score, which 
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tests the future neurobehavioral development first at one minute 
after birth, then five minutes after and after ten minutes after 
birth. The results favored the group of children not exposed to 
chemotherapy at one and five minutes, but there were no sig-
nificant difference at ten minutes. Although it reflects positive 
short-term outcomes, it’s limited in long-term follow up on these 
children and researchers suggest further studies need to be per-
formed (Abdel-Hady, et al., 2012). 
Fetal cardiotoxicity was also researched to determine whether 
it can develop from maternal chemotherapy and pose a threat 
to neonates. One study consisted of ten pregnant patients treat-
ed with anthracyclines in the last two trimesters to investigate 
whether these drugs, which are thought to cause fetal cardiotox-
icity, can result in fetal cardiac abnormality. The results indicated 
that one fetus was diagnosed with fetal supraventricular tachy-
cardia, but researchers believed it was unrelated to maternal che-
motherapy.  Additionally, differences in myocardial performance 
index and in the tricuspid inflow pattern were detected, but were 
considered clinically insignificant. The neurological development 
and weight, height, and clinical examination of the fetuses in the 
study group were within normal limits. Significant cardiac abnor-
mality and intrauterine growth restriction were not detected, al-
though low birth weight was observed. Although the researchers 
gathered data systematically, the study was small and therefore 
limited (Gziri, et al., 2012). 
Long Term Effects
A concern of maternal chemotherapy is the long-term cardiotoxic 
effects on the fetus. A study used tissue Doppler and strain imaging 
to identify any specific changes in cardiac performances that might 
result from chemotherapeutic drug. The study focused on children 
exposed to anthracylines, a drug shown to cause cardiomyopathy 
and cardiac dysfunction.  The children’s ages ranged from 1-9 years 
old, with the mean age being 1.7 years old. Those exposed to anth-
racyclines were observed to have minor changes in left ventricular 
(LV) wall thickness that might have occurred from the effect of 
anthracycline’s toxicity. Anthracycline is known to lead to loss of 
cardiac muscle. There was also indication that there might be a 
lower, but normal ejection fraction and left ventricular ejectional 
fractional shortening, which is not clinically important since there 
is no change in functionality. Since there were no differences in tis-
sue Doppler and strain imaging between the control group and pa-
tients, researchers indicated that there was no change in myocardi-
al function. They stated that changes recorded could have resulted 
from the fact that the majority of the neonates born were preterm. 
Overall, their observation showed that there was no significant 
change between the 62 patients and 62 age gender-matched con-
trols. Researchers recommended further research to observe any 
future irregularities and suggested performing further studies with 
larger patient groups with proper follow up (Gziri, et. al., 2013).
Further research was performed to assess the neurodevelop-
ment, cardiac function, and general health of 70 children who 
were exposed to chemotherapy in utero. Seventy children from 
68 pregnancies (two twin pregnancies) were assessed at age 18 
months and at ages 5–6, 8–9, 11–12, 14–15, or 18 years.  The me-
dian gestational age at birth was 35.7 weeks, with a median fol-
low-up period of 22.3 months. Most of the children had normal 
cognitive development. However, children who were born pre-
maturely had lower cognitive development scores albeit within 
normal range of cognition.   Moreover, for each additional month 
of gestation, the IQ score increased by an average 11.6 points. 
Therefore, iatrogenic preterm delivery is not suggested since it 
significantly impacts the cognitive development. 
Additionally, because the CNS continues to develop after the 
first trimester, the possibility that maternal chemotherapy may 
adversely affect neurological development is a serious concern 
(Gziri, et al., 2012). However, only one set of twins of 70 children 
observed experienced severe neurodevelopmental delay. This 
cannot be completely attributed to the exposure to a chemo-
therapeutic drug (Amant, et al., 2012). The cortex of the fetal 
brain develops surface sulci and gyri at 14 weeks gestational age 
and doesn’t remain the original smooth cerebral surface. The for-
mation of polymicrogyria, in which the cerebral cortex develops 
abnormally before birth in the deeper layers and excessive gyri 
form, removes some of the probability that chemotherapy expo-
sure after 15 weeks instigated the developmental delay observed 
in the twins (Amant, et al., 2012; Barkovich, et al., 2010). Yet, the 
researchers did acknowledge that although the neurodevelop-
ment was normal in the overall researched group, subtle changes 
could occur and further research on longer follow-ups should 
be conducted.
Nonetheless, the average results of the children’s behavior, gen-
eral health, hearing, and growth were within the normal range, 
along with their cardiac dimensions and functioning. No increase 
in CNS morbidity was recorded. Although there were no con-
genital cardiac abnormalities detected, further study was recom-
mended on the cardiac function since there were clinically small, 
but statistically significant changes in ejection fraction, fractional 
shortening and diastolic variables. They did detect, however, a 
higher incidence of disharmonic intelligence profiles. The results 
of the Wechsler test depicted a discrepancy between verbal 
and performance IQ values. This was seen in 39% of patients in 
comparison to 15% in the normal population. The discrepancy 
has been associated with several neurological disorders, learning 
problems and behavioral issues. 
The study was limited due to the small sample size, short fol-
low-up periods, and lack of children born at the same gestational 
age and similarly assessed, who were not prenatally exposed to 
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chemotherapy. Additionally, researchers could not predict if sec-
ondary malignancy and infertility would have developed due to 
time constraint of the experiment. Only one twin, who also had 
congenital malformation, was diagnosed with secondary malig-
nancy and suffered from papillary thyroid cancer at age eleven 
and neuroblastoma at age fourteen. 
Nonetheless, the researchers suggested that chemotherapy not 
be administered after 35 weeks since this can trigger sponta-
neous labor. Delivery, they stated, should be arranged to be no 
less than three weeks after the last chemotherapy cycle. This en-
sures that the bone marrow recuperates properly, prevents the 
development of fetal and maternal sepsis and hemorrhage and 
hematological toxicity. As mentioned, preterm delivery should be 
avoided due to the impact on cognitive development. Preterm 
neonates are limited in their capacity to metabolize and elimi-
nate drugs since they have immature liver and kidneys. Therefore, 
if delivery can be postponed, the fetus can excrete the drug 
through the placenta instead.
The positive outcome led the researchers to conclude that there 
are three factors that may reduce the risks associated with ma-
ternal chemotherapy. First, is that maternal chemotherapy admin-
istration should be given after the first trimester, as this avoids 
the period of increased susceptibility of the fetus to toxicity. 
Secondly, they believe that the fetal blood brain barrier protects 
the brain from drug diffusion with tight junctions and decreas-
es rates of transcytosis and expression of specialized influx and 
efflux transporters, such as P-glycoprotein. Furthermore, vascu-
lar permeability and CNS immune cell infiltration is decreased 
through the inhibition of pericytes. Lastly, they suggest that the 
fetus is protected since the plasma filters the chemotherapeutic 
drugs (Amant, et al., 2012).
The most reassuring study which demonstrated the safe use of 
maternal chemotherapy was the observation on the long-term 
effect on 84 children/adults with a follow-up period of 6-29 years. 
The mothers of these children were diagnosed with hematologi-
cal malignancies, and were treated with intense chemotherapeutic 
agents given in adequate doses. The treatments, however, varied 
in which trimester the dosage was administered. Observations of 
the children/adults reported that the height, weight, birth and cy-
togenetic material were normal and that there was no evidence 
of cellular damage. Additionally, educational performance and 
neurological and psychological evaluations were on par with the 
general public. Furthermore, sixteen of patients were married, 
with twelve children born in total, who also did not suffer from 
any abnormalities. Although many doctors disagree, research-
ers in this study suggest that treatment can be given in the first 
trimester due to their positive results (Aviles, Neri, 2001). This 
gives positive encouragement to pregnant cancer patients since 
it provides concrete evidence that the fetus can escape harm and 
develop normally into a healthy accomplishing adult.
Conclusion
Overall, transplacental transfer of cytotoxic drug is not detect-
ed in all of the treatments and its impact varies based on the 
physiologic changes in pregnant women and the pharmokinetics 
of drugs administered. Many emphasize that chemotherapeutic 
agents should certainly be delayed and only be given after the 
first trimester since the fetus is highly vulnerable to teratogenic-
ity. When given in the final two trimesters, risks can still persist. 
However, this should not prevent the mother from seeking treat-
ments due to insignificant short-term and long-term effects. 
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